Author Interviews, Connective Tissue Disease / 17.05.2014
SLE: BAFF Antagonist For Treatment of Severely Active Disease
MedicalResearch.com Interview with:
Dr Renee Martin
Anthera Pharmaceuticals, Inc.
25801 Industrial Blvd, Suite B.,
Hayward, CA 94545,
MedicalResearch: What are the main findings of the study?
Dr. Martin: The PEARL-SC study identified many key elements that inform the further development of blisibimod for treatment of SLE:
i. That patients with severely active disease responded well to blisibimod,
ii. That a dose of 200mg blisibimod administered subcutaneously once per week improved measures of SLE disease activity,
iii. That greater treatment effect was observed when the SRI-7 and SRI-8 endpoints were evaluated, presumably because the criteria for these endpoints (including 7- or 8- point improvements in SELENA-SLEDAI score, respectively, along with no new BILAG A or 2B scores, and no worsening of physician’s global assessment score) demand substantial improvement in disease activity compared with baseline, and are unlikely to be met by chance (e.g. in the placebo group), and
iv. That blisibimod was safe and well-tolerated over 24-52 weeks of continuous therapy.





calResearch.com Interview with:
Jennifer G. Robinson, MD, MPH
Professor ,Departments of Epidemiology & Medicine
Director, Prevention Intervention Center
Department of Epidemiology
College of Public Health
University of Iowa
Iowa City, IA 52242-2007
MedicalResearch: What are the main findings of the study?
Dr. Robinson: The PCSK9 antibody, evolocumab, reduced LDL (or bad) cholesterol by about 65-70% regardless of the dose or type of statin used. This is a greater percentage reduction than ezetimibe, another drug used to lower LDL cholesterol in statin-treated patients, which lowered LDL cholesterol 15-20%. Side effects of evolocumab were similar to those for ezetimibe or placebo.












